ClinicalTrialsFinder
RecruitingNCT05550961

APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch

Sponsor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Enrollment

1,200 participants

Start Date

Oct 1, 2022

Study Type

OBSERVATIONAL

Conditions

Lung CancerCancerNSCLCAdenocarcinoma of LungSquamous Cell Lung Cancer

Summary

APOLLO 11 main aim is to build a strong Italian long-lasting lung cancer network (in around 48 Italian centres) on real world data and translational research by creating a decentralized long-term national database (settle locally in each centre) and a "virtual" multilevel biobank in each centre. Besides, APOLLO 11 will take advantage of the translational research joint effort with the credo "unity is strength".

Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Provision of signed and dated written informed consent, when applicable, by the patient or legally acceptable representative prior to any mandatory study-specific procedures, sampling, and analyses;
  • Patients must be ≥18 years of age at the time of signing the informed consent;
  • Histologically or cytologically confirmed lung cancer (NSCLC or SCLC) at any stage (I-IV) candidate to receive or already treated with innovative therapies (ICIs, target therapies and next generation therapies).

Exclusion Criteria5

  • Patients who are or will be taking other unapproved antineoplastic therapies concurrently are not eligible.
  • Patients who have not received an oncological systemic innovative therapy at any setting
  • Patients received only local treatments (e.g., only surgery, or only radiotherapy)
  • Patients who received only standard chemotherapy are excluded.
  • Patients who received treatment therapies before 2010 are excluded.

Locations(1)

Fondazione IRCCS Istituto Nazionale dei Tumori

Milan, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05550961

Related Trials

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

NCT046786483 locations

Virtual Agent Feasibility in Oncology Patients (NTT Data)

NCT066820131 location

Lung Cancer Screening in HIgh Risk nonsmokErs by Artificial inteLligence Device

NCT062954971 location

Empathic Communication Skills (ECS) Training

NCT0545684112 locations

A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer

NCT0407709940 locations